AngioInsight, Inc. — SEC Form D Filing
AngioInsight, Inc. filed an SEC Form D on November 10, 2026, reporting $16.31M raised in Healthcare AI & Diagnostics.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 10, 2026
- Amount reported
- $16.31M
- Round stage
- Seed
- Industry
- Healthcare AI & Diagnostics
- Website
- https://www.angioinsight.com/
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Standard angiography relies on subjective visual assessments and often fails to detect abnormalities in small blood vessels, leading to coronary microvascular disease (CMD) being frequently underdiagnosed or misdiagnosed, especially in women.
Solution
AngioInsight is developing the AngioAI+ software platform, which analyzes standard angiographic video to assess stenosis, physiology, and microvascular function. The platform combines Coronary Artery Disease and Coronary Microvascular Disease evaluations into a single automated workflow without requiring additional hardware.
Why now
Growing clinical awareness of ischemia with non-obstructive coronary arteries (INOCA/CMD) coincides with advancements in AI computer vision capable of extracting physiological insights from existing fluoroscopy workflows.
Verdict
This cleared because investors bought a software-only wedge to eliminate expensive, invasive pressure wires in the cath lab, not because they believed microvascular AI would instantly command new standalone reimbursement. Backing a $16.3M seed meant betting that interventionalists will trust computer vision over physical sensor wires to diagnose both macro- and microvascular disease. The upside remains capped by the reality that cath lab software is historically absorbed or commoditized by C-arm imaging incumbents before achieving standalone venture scale.
Source: SEC EDGAR Form D filing